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RESEARCH ARTICLE
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Abstract
Background
A homologue of the ecdysone receptor has previously been identified in human filarial para-
sites. As the ecdysone receptor is not found in vertebrates, it and the regulatory pathways it
controls represent attractive potential chemotherapeutic targets.
Methodology/ Principal Findings
Administration of 20-hydroxyecdysone to gerbils infected with B.malayi infective larvae dis-
rupted their development to adult stage parasites. A stable mammalian cell line was created
incorporating the B.malayi ecdysone receptor ligand-binding domain, its heterodimer part-
ner and a secreted luciferase reporter in HEK293 cells. This was employed to screen a
series of ecdysone agonist, identifying seven agonists active at sub-micromolar concentra-
tions. A B.malayi ecdysone receptor ligand-binding domain was developed and used to
study the ligand-receptor interactions of these agonists. An excellent correlation between
the virtual screening results and the screening assay was observed. Based on both of these
approaches, steroidal ecdysone agonists and the diacylhydrazine family of compounds
were identified as a fruitful source of potential receptor agonists. In further confirmation of
the modeling and screening results, Ponasterone A and Muristerone A, two compounds
predicted to be strong ecdysone agonists stimulated expulsion of microfilaria and immature
stages from adult parasites.
Conclusions
The studies validate the potential of the B.malayi ecdysone receptor as a drug target and
provide a means to rapidly evaluate compounds for development of a new class of drugs
against the human filarial parasites.
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Author Summary
The human filarial parasites are the causative agents of two neglected tropical diseases tar-
geted for elimination by the international community. The current elimination programs
rely upon the mass distribution of a limited number of drugs, leaving the programs open
to failure in the event that resistance develops. Thus, there is a critical need for novel che-
motherapeutic agents to supplement the current arsenal. The filarial parasites are ecdy-
sozoans, whose developmental processes are controlled by a master regulator, the
ecdysone receptor. Here we validate the potential of the filarial ecdysone receptor as a che-
motherapeutic target and report the development of high throughput and virtual screen-
ing assays that may be used to compounds that target it.
Introduction
Diseases caused by the human filarial parasitic nematodes are a significant public health prob-
lem faced by developing countries. Recent reports estimate that there are over 140 million indi-
viduals suffering from human filarial parasites in over 80 countries worldwide. Approximately
1 billion people are at risk for contracting the filarial infections [1]. Lymphatic filariasis (caused
by infection with Brugia malayi, Brugia timori orWuchereria bancrofti) and onchocerciasis
(caused by infection with Onchocerca volvulus) are severely debilitating diseases, together
resulting in a loss of 5.7 million disability adjusted life years [2].
Both lymphatic filariasis (LF) and onchocerciasis have been designated as neglected tropical
diseases by the international community, and both have been targeted for elimination in the
London Declaration on Neglected Tropical Diseases (NTDs) [3].
The efforts to eliminate LF and other NTDs have generally relied on mass drug administra-
tion (MDA) programs. Currently, a combination of ivermectin plus albendazole (ALB) or
diethylcarbamazine (DEC) plus ALB are employed for MDA for filariasis (depending upon the
region), while ivermectin (IVM) monotherapy is the standard for MDA targeting onchocercia-
sis. However, recent clinical trials with a single-dose triple-drug therapy of DEC, IVM and
ALB [4], and twice-yearly treatment with ALB + IVM [5] have shown very promising results
when compared to the two-drug regimens currently used by traditional filariasis MDA
programs.
Though MDA programs have on the whole been well formulated and executed, they face
potential challenges that may threaten their ultimate success. These include the development
of resistance to the limited number of drugs that are deployed by the MDA programs [6] and
limits on the use of MDA in certain areas. For example, DEC + ALB is used to treat LF by
MDA programs throughout India, South America and Southeast Asia [7,8]. However it cannot
be used in Africa, as it causes severe ocular side effects and systemic complications in individu-
als co-infected with O. volvulus, the causative agent of onchocerciasis, a disease that is endemic
throughout most of sub-Saharan Africa [9,10]. Similarly, ivermectin, which is the only drug
used by the MDA programs worldwide to treat onchocerciasis, cannot be easily used in much
of Central Africa. This area is endemic for the eyeworm Loa loa, and treatment of L. loa
infected individuals with ivermectin can result in severe neurological reactions, including coma
and death [11]. Thus, new treatments are desperately needed for these infections.
Insect growth regulators (IGRs) have been used in veterinary medicine to treat ectoparasites
like ticks, fleas, lice and mites. The IGRs interfere with the larval molt and embryogenesis by
targeting one of two pathways: (i) chitin inhibitors acting on cuticle synthesis and degradation,
and (ii) hormonal (ecdysone and juvenile hormone) analogs [12]. Ecdysteroids are master
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regulators of development in arthropods, and are thought to also play a central role in control-
ling development in other organisms in which molting is a central feature of the life cycle (the
ecdysoans) [13]. In insects, molting and other developmental processes (including embryogen-
esis) are controlled through variation in the levels of the molting hormones, or ecdysteroids,
which induce molting, and the juvenile hormones, which inhibit molting [14,15]. This process
is mediated through a heterodimer of the ecdysone receptor (EcR) and ultraspiracle, the homo-
logue of retinoid X receptor (RXR) which controls the transcriptional activity of the develop-
mental genes regulating molting and metamorphosis [16]. The fact that ecdysis is a central
developmental pathway in insects and is absent in vertebrates has made it an attractive target
for the development of compounds that might act selectively against invertebrates [17,18].
Thus, the agricultural industry has targeted the EcR in pesticide development, as insects repre-
sent one of the largest classes of ecdyzoans on Earth. This high degree of species-specific activ-
ity makes the EcR an excellent target for pest management. For example, tebufenozide has
insecticidal activity against lepidopteran pests but shows low activity against the hymenopteran
insects [18].
Several lines of evidence suggest that like insects, many developmental processes in parasitic
nematodes may be controlled in part by ecdysteroids. First, ecdysone and related compounds
have been found in many parasitic nematodes, including O. volvulus (for a review, see [19]).
Second, ecdysteroid levels vary during nematode development. In Ascaris suum, the level of
20-hydroxyecdysone (20E) has been shown to peak just before the third and fourth larval
molts, similar to the temporal pattern seen during the larval molts in insects [20]. Third, para-
sitic nematodes are capable of catabolizing ecdysone [21]. Fourth, ecdysteroids have been
shown to have developmental effects on parasitic nematodes. For example, ecdysone was
shown to stimulate microfilarial release in Brugia pahangi and to promote embryogenesis in
ovaries of D. immitis adult females [22]. Fifth, a homolog of the EcR has been identified and
proven to be functional in Brugia malayi [13,23]. Homologues of the EcR have also been iden-
tified in the genomes of other human filarial parasites. Previous studies have demonstrated
that treatment of the filarial worm with ecdysteroids can affect embryogenesis [23], molting
[24] and viability of adult parasites [25], suggesting that the EcR might represent an attractive
chemotherapeutic target against filarial infections. In this study, we validate the Brugia malayi
ecdysone receptor (BmaEcR) as a chemotherapeutic target and report progress towards the
development of a high-throughput screening assay to identify agonists and antagonists against
the BmaEcR. We also report the development of a homology model of the BmaEcR that may
be useful in optimizing leads identified by high throughput and in-silico approaches.
Materials and Methods
Ethics statement
All animal work was conducted according to guidelines outlined by the National Institutes
of Health Office of Laboratory Animal Welfare, and was approved by The Institutional Ani-
mal Care and Use Committee (IACUC) of the University of South Florida, under protocol
IS00000261.
Infection and 20-hydroxyecdysone (20E) treatment of gerbils
Brugia malayi infective larvae (L3) were obtained from the Filariasis Research Reagent
Resource Center (FR3) at the University of Georgia, USA. A total of four male gerbils were
infected intraperitoneally with 150 L3s each, under aseptic conditions. The experimental ani-
mals (n = 2) received 20E (Adipogen, CA) at a dose of 5mg/kg/day/animal for 150 days. The
control animals (n = 2) received ethanol, the vehicle used for dissolving 20E. To avoid the
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potential for trauma induced by having to carry out multiple gavages on each animal, Alzet
mini-osmotic pumps (Model number 2006) were used to provide a steady supply of 20E in eth-
anol or ethanol alone to the infected animals. The pumps were surgically implanted on the dor-
sal aspect of the gerbils two days post-infection. The pumps were replaced every 42 days
following the manufacturer’s instructions. Animals were euthanized after 150 days post-infec-
tion and peritoneal gavage was performed to recover microfilariae. Necropsy was then con-
ducted to recover adult worms from the peritoneal cavity.
Constructs for creating stable cell line
Previous studies utilized a system in which plasmids were transiently transfected into NIH3T3
cells (American Type Culture Collection- www.atcc.org; CRL-1658) [13]. However, in our
studies the plasmids were transfected into HEK293 cells (American Type Culture Collection-
www.atcc.org; CRL-1573) as we observed improved growth and enhanced assay characteristics
when these cells were used. To adapt the transient transfection assay into a high throughput
screen, a stable mammalian cell line was developed, in which all three of the necessary con-
structs were integrated into the HEK293 genome, employing the Gateway recombination sys-
tem (Invitrogen, CA). In brief, three cassettes were constructed. The first cassette consisted of
the ligand-binding domain (LBD) of the BmaEcR fused to a heterologous GAL4 DNA binding
domain. This fusion ORF was placed under the control of the CMV intermediate early pro-
moter and terminated with an Sv40 poly-A addition signal. The second cassette contained the
open reading frame (ORF) for the human RXR chimera fused to the VP16 activation domain.
This chimeric ORF was placed under the control of the SV40 promoter and terminated with
the bovine growth hormone poly-A addition signal. Finally, a reporter Gaussia princeps
secreted luciferase reporter ORF was created that was preceded by five copies of the GAL4
response element and a minimal promoter. The reporter ORF was terminated with the human
B globin poly-A addition signal. All cassettes were prepared using standard molecular cloning
procedures and amplified by PCR with appropriate primers to produce products ready for
recombination cloning. The three cassettes were then cloned by recombination into three
pDONR vectors of the multisite Gateway Pro system (S1 Fig). The sequence of the resulting
entry clones were confirmed and the functionality of the entry clones confirmed by transiently
transfecting all three pDONR plasmids into HEK293 cells and testing for reporter activity in
cells cultured in the presence and absence of 20E, as described below. The entry vectors were
then inserted by three-way recombination into the destination vector pJTI Fast Dest (Invitro-
gen, CA) to create a destination vector containing all three cassettes (S1 Fig). This construct
was validated by DNA sequencing and by functional assays, as described above. The destina-
tion vector was then used to create a stable mammalian cell line in HEK293 cells, using the
Jump In Fast Gateway Targeted Integration System (Invitrogen, CA). Clones were selected in
the presence of 30ug/mL hygromycin following the manufacturer’s protocol, and individual
clones selected and screened for reporter expression in the presence and absence of 20E, in
order to identify the clone producing the greatest signal to noise ratio and minimal well-to-well
variation. The clone that exhibited highest signal to noise ratio was cultured and maintained in
T75 flasks using 1x MEMmedia fortified with 10% FBS.
Screening strategy and screening of ecdysone agonists
An ecdysone analog library consisting of compounds found to be active against various insect
species was tested against the BmaEcR [26–28]. Thirty-five thousand cells of the cell line devel-
oped as described above were seeded into each well of a 96 well tissue culture plate. The cells
were grown under the same conditions as described above. Cells were incubated at 37°C for
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18–24 hours until they reached a density of 70–90%. Compounds were added to wells contain-
ing the cells at a concentration of 10μM and the cells incubated in the presence of the com-
pounds for 48 hours. Control wells received ethanol, the vehicle of 20E. A total of 10μl of the
culture media was removed from each well, and assayed for the presence of secreted luciferase
using the renilla assay reagent in the Dual Luciferase assay kit (Promega, WI) following the
manufacturer’s protocol. Each compound was assayed in triplicate. Student’s t-test was used to
calculate the significance of any agonist activity observed, and the Bonferroni correction was
applied to the results to adjust for multiple comparisons. Tenfold dilutions of compounds that
resulted in a statistically significant increase in reporter activity (p< 0.05, Bonferroni cor-
rected) were then assayed in triplicate to calculate EC50 values. To assess cytotoxic effects of the
compounds on the mammalian cell line, cell viability was assayed with Alamar Blue (Thermo-
Fisher Scientific, MA) according to manufacturer’s protocol. Z’ values for the assay were calcu-
lated as previously described [29].
Homology model construction, validation and refinement
The tertiary structure of the BmaEcR was predicted using the Schrödinger’s Prime 3.1 compar-
ative homology modeling module (Prime. Schrodingers, LLC New York, NY version 3. ed.
2012) [30]. Due to the lack of an experimental crystal structure of the BmaEcR, a search for
suitable template structures upon which to model the BmaEcR tertiary structure was under-
taken using BLAST (Basic Local Alignment Search Tool) [31]. The hemipteran Bemisia tabaci
EcR (PDB ID: 1Z5X) was predicted to be the template with highest homology to BmaEcR
(BLAST-bit score: 145.2) with excellent residue conservation. Based on the template secondary
structure, Clustalω [32] was used to optimize the placement of the BmaEcR (LBD) α-helices
and β-sheets using a hidden Markov model (HMM). After the Clustalω alignment, backbone
atoms for aligned regions and conserved residue side chain atoms were directly transferred
from the template to the query sequence to create an initial structure, followed by adding inser-
tions and closing gaps using a knowledge based approach. The B. tabaci EcR native substrate
ponasterone A was retained in the binding site during the homology model construction. The
prime serial loop sampling protocol was used to refine one particular loop of importance (resi-
dues 162–175) that constitutes an intrinsic part of the binding site. To alleviate possible steric
clashes between residues after model construction, Truncated Newton Conjugate Gradient
(TNCG) minimization was performed using implicit solvent (VSGB 2.0) with the OPLS-2005
force-fields, until convergence was reached (< 0.01 kcal.mol-1 Å-1) [33]. The quality of homol-
ogy model was verified by generating Ramachandran plots and further compared to the
homology model generated with the I-Tasser web-server (details in S1 Appendix) for addi-
tional structural validation purposes [34]. To further refine the homology model, Molecular
Dynamics (MD) simulations were performed for 65 ns while monitoring structural properties
such as radius of gyration (Rg), root mean square deviation (RMSD), root mean square fluctua-
tion (RMSF), and total energy of the system (details in S1 Appendix). A snapshot of the
BmaEcR homology model that was most representative of the complete 65 ns simulation (i.e., a
snapshot that likely details biologically relevant conformations) was selected according to a
simulation-clustering scheme (S1 Appendix); this structure was used for subsequent molecular
docking studies.
Molecular docking studies
All ligand structures were prepared using Schrödinger’s LigPrep 2.3 [35] module to produce
appropriate 3D structures with correct stereochemistry, protonation states, and ring conforma-
tions. All ligands were then virtually docked in the BmaEcR homology model using the Glide
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5.8 docking program. Glide uses a user-defined grid to determine the shape and properties of
the binding site. The BmaEcR grid was defined by selecting the centroid of ponasterone A with
otherwise default settings. The ligands were first docked and scored according to Glide SP
(standard precision) and then re-docked with the Glide XP (extra-precision) protocol. Glide
Scores (GScores) were calculated to estimate the relative predicted binding affinity amongst the
ligands for the EcR binding site [36]. As part of the default Glide docking procedure, the van
der Waals radii of non-polar hydrogen atoms were scaled by a factor of 0.8 and all calculations
were performed with the OPLS-2005 force field.
Validation of in-silico screening model
To illustrate the utility of combining virtual screening results with experimental assays, we gen-
erated a small virtual compound library to identify potential novel BmaEcR LBD hits. This
small library was assembled from searches done on extensive and diverse online databases (i.e.,
the PDB and PubChem). The initial search used the ProBiS-CHARMMing / ProBiS-Ligands
structural bioinformatics tool (available at http://probis.nih.gov), which compares the binding
site of a provided structure to all known protein binding sites in the non-redundant PDB (cur-
rently 42,270 in total) [37,38]. The BmaEcR homology model was submitted to ProBiS, with
the EcR LBD identified as the binding site of interest. Four proteins were identified with similar
binding sites to the EcR LBD and each of these binding sites had several associated ligands; all
of these were added to our virtual library. Secondly, a ponasterone A structure similarity search
was performed on the PubChem compound library (consisting of ~83 million compounds)
[39]. Ultimately, 104 compounds were identified via the two search protocols and added to the
virtual library.
This library was then virtually screened according to the following protocol: (1) compounds
were docked in the EcR LBD with Glide SP, (2) structures that resulted in binding scores of
-7.25 kcal/mol (the binding score of 20-hydroxyecdysone) were re-docked into the EcR LBD
using Glide XP docking, and again (3) those structures with Glide XP docking scores of less
than -7.25 kcal/mol were docked into the EcR LBD with a flexible ligand-flexible receptor
docking method known as Induced Fit Docking (IFD) [40,41], which allows for better binding
mode prediction, albeit at a higher computational cost [42–44].
Four of the compounds identified by the virtual screen (AM580, BMS493, 22-R-Hydroxy-
cholesterol, TTNPB) were found to be readily commercially available. These were obtained
from Sigma-Aldrich (St. Louis MO, USA), and tested for activity and cytotoxicity using the
assays described above.
In-vitro phenotypic studies comparing the effect of Muristerone A and
Ponasterone A with 20E
Adult females were cultured in a 6-well plate (five parasites per well) in CF-RPMI media
(RPMI 1640 supplemented with 25 mMHEPES buffer, 2 mM glutamine, 100 U/ml streptomy-
cin, 100 μg/ml penicillin, 0.25 μg/ml of amphotericin B, and 10% heat-inactivated fetal calf
serum). Two biological replicates were conducted per treatment group. Parasites were allowed
to acclimatize for 24 hours before treatments commenced. After the acclimatization period,
Muristerone A, Ponasterone A and 20E (separate wells) were added to a final concentration of
10 μM to the experimental wells. The control wells received ethanol (the vehicle for ponaster-
one A, muristerone A and 20E). The parasites were then cultured for an additional four days.
The culture media was changed every 24 hours. Three 20ul aliquots from each biological repli-
cate were removed every 24 hours from each well and the number of progeny present (aborted
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eggs and embryos, immature microfilariae and mature microfilariae) counted. Thus, three
technical replicates were performed on each biological replicate at each time point.
Results
Previous studies have demonstrated that 20E stimulated expulsion of immature progeny (eggs,
embryos and immature microfilariae) from adult female parasites cultured in the presence of
20E [45]. However, by analogy to its role in insects, the BmaEcR could be hypothesized to play
an important role in molting in the filarial parasites as well. To test this hypothesis, the effect of
20E on the development of infective larvae to the adult stage was assessed in gerbils intraperito-
neally infected with B.malayi infective larvae. Infected animals were given 20E at a dosage of
5mg/kg/day for a total of 150 days, the time necessary for infective larvae to develop into fertile
adult parasites. After 150 days, the animals were euthanized and the peritoneal cavity was
examined for parasites. A total of 25 and 28 adult female parasites respectively were recovered
from the peritoneal cavity of the two control animals given only ethanol, the vehicle for 20E
(Fig 1A). In contrast, no parasites were recovered from one of the animals given 20E, while a
single incompletely developed female parasite was recovered from the second 20E treated ani-
mal (Fig 1B and 1C). In keeping with this observation, a large number of mature microfilariae
were recovered from both control animals while no microfilariae were observed in the perito-
neal cavity of the two treated animals.
Previous studies have demonstrated that mammalian cells transiently transfected with three
plasmids containing ORFs for the BmaEcR LBD domain, a heterodimeric RXR partner and a
secreted luciferase reporter exhibited an up-regulation of reporter activity when cultured in the
presence of ponasterone A, a potent ecdysone analog [13]. Mean luciferase activity in the
Fig 1. In-vivo phenotypic study demonstrating effects of 20-hydroxyecdysone on adult worms. (A)
Graph showing recovered parasites from the study animals after necropsy. (B) Control worm showing normal
length of the adult female parasite. (C) Ecdysone treated worm showing stunted growth and shorter length.
doi:10.1371/journal.pntd.0004772.g001
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media of HEK293 cells transiently transfected with these three plasmids increased roughly
seven-fold when compared to the reporter activity in the media of cells cultured in the absence
of 20E (Fig 2A). The Z’ calculated for this assay was 0.72, suggesting that an assay based upon
such a platform might be suitable for use in a high throughput format to identify agonists or
antagonists for the BmaEcR. However, the transient transfection process varied in efficiency
from day to day and the need to repeatedly transiently transfect cells limited the throughput of
the assay, both of which were impediments to adapting the assay to a high throughput format.
To overcome these obstacles, a stable cell line was created that incorporated the three cassettes
necessary for the assay (the BmaEcR LBD, the RXR partner and, the reporter) into the genome
of HEK293 cells. Assays using the stably transfected cells revealed a performance comparable
or better than that of the assay using the transiently transfected cells, with a signal to noise
Fig 2. Performance of the mammalian cell assay. Results of a typical assay carried out in a 96 well format
are shown. Columns indicate the mean and error bars the standard deviation of six control (uninduced) and
six experimental (induced) wells. (A) Assay conducted with the transiently transfected cells with 150ng per
well of each construct (BmaEcR- GAL4, RXR-VP16, GLuc reporter) using Lipofectamine, and treated with
10μM 20-hydroxyecdysone for 48 hrs. (B) Assay conducted with the stably transfected cells.
doi:10.1371/journal.pntd.0004772.g002
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ratio ranging from 4.5 to 5.5 and a Z’ that ranged from 0.78 to 0.88 when conducted on differ-
ent days (Fig 2B).
The stably transfected cells were used to screen a focused library comprised of 40 com-
pounds belonging to the diacylhydrazine, tetrahydroxyquinoline and the steroidal ecdysone
analog families. These compounds were tested for activity against BmaEcR using the screening
strategy described in Materials and Methods. The initial screen identified seven compounds
that resulted in a significant increase in reporter activity in the stable cells cultured as compared
to the activity in the cells cultured in the presence of solvent alone (Fig 3, p< 0.05, with Bonfer-
roni correction for multiple comparisons). In particular, muristerone A and ponasterone A
demonstrated a higher level of activity than 20E in this assay.
The compounds identified as agonists were then tested at a series of concentrations to deter-
mine the EC50 values. The EC50 values for the initial hits were low, with some exhibiting values
that were in the sub-μM range (Fig 4). None of the compounds exhibited cytotoxicity at a con-
centration of 10 μM.
A homology model of the BmaEcR LBD was then constructed as described in Materials and
Methods. The Ramachandaran plots before and after MD simulations were created to discern
potential changes in ϕ /ψ distributions. The number of residues within the favored and allowed
regions increased from 89.6% to 98.7% as a result of MD simulations (S2 Fig). Fig 5 presents
Fig 3. Compounds identified in the screen of compounds active against the BmaEcR. Cells were treated with 10μM of each drug for
48 hrs. The blue bars represent all other compounds tested; 20E is represented as green bar and the red bar indicates the activity present in
untreated cells. All columns represent the mean and the error bars the standard deviation in triplicate wells. The horizontal line indicates the
activity expected for compounds with no activity.
doi:10.1371/journal.pntd.0004772.g003
Therapeutic Potential of B.malayi Ecdysone Receptor
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Fig 4. EC50 values and structures of compounds identified in the preliminary screen of compounds
interacting with the BmaEcR using the cell-based luciferase assay.
doi:10.1371/journal.pntd.0004772.g004
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the structure of the B.malayi EcR LBD homology model with Ponasterone A occupying the
active site.
The homology model was used for virtual screening studies of agonists identified with the
molecular assay above to verify the model performance. The structure with the most favorable
protein—ligand interaction energy based on the MD simulation (according to an RMSD clus-
tering scheme of the final 20 ns) was chosen as the representative structure for molecular dock-
ing studies (details in S1 Appendix). The 3D structures of the ligands were docked and scored
using both Glide SP (standard precision) and Glide XP (extra precision) (Fig 6). The predicted
lowest energy for each agonist (ligand) is described in detail in the S1 Appendix and S2 Table.
A comparison of computational and experimental results is shown in Table 1. A Pearson corre-
lation coefficient of 0.78 was found between experimental log EC50 values and Glide XP dock-
ing scores, suggesting that the model predictions trended well with the data collected from the
mammalian cell assay.
As a first test of the utility of the model to identify potential compounds capable of interact-
ing with the BmaEcR, a number of databases were initially screened as described in Material
and Methods, resulting in a library of 104 potential hits. A total of 25 compounds survived the
selection protocol described in Materials and Methods (i.e. had Glide XP predicted binding
scores more negative than -7.25 kcal/mol). The binding modes of these 25 compounds were
further refined via flexible ligand—flexible protein docking (i.e., IFD). The docking scores for
Fig 5. Cartoon depiction of the B.malayi EcR LBD homologymodel. The secondary structural element
are colored in purple. The red dotted circle denotes the active site for the docking studies.
doi:10.1371/journal.pntd.0004772.g005
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these 25 compounds are shown in S3 Table. Of particular note, two compounds found to be
active were isolated without using the ligand’s structural information (i.e., were obtained via
ProBis CHARMMing / ProBis Ligands). Out of these 25 compounds, four (AM580, BMS493,
22-R-Hydroxycholesterol, TTNPB) were commercially available. When tested on the cell-
based assay, AM580 and BMS493 were active agonists with micromolar EC50 values (Fig 7).
The remaining two compounds (22-R-Hydroxycholesterol and TTNPB) were found to be
cytotoxic at all concentrations tested, and could not be evaluated in the cell based assay.
As mentioned above, previous studies have demonstrated that culturing gravid adult
females in the presence of 20E induced expulsion of immature eggs, embryos and microfilaria.
Ponasterone A and muristerone A were the compounds that gave a better performance than
20E in the cell assay as well as having a high predicted binding score in the active site of the
Fig 6. Predicted structures of agonists docking in the active site of the homologymodel of the BmaEcR LBD. (A-D) The panels
show 20-hydroxyecdysone, ponasterone A, muristerone A and diacylhydrazine #28 binding into the active site.
doi:10.1371/journal.pntd.0004772.g006
Table 1. XP descriptor analysis given from XP docking of hormones and agonists in B.malayi EcR-LBD binding site.
Compound EC50 μM Log EC50 GScore
20-Hydroxyecdysone 2.34 0.37 -7.25
Muristerone A 0.05 -1.3 -8.28
Ponasterone A 0.04 -1.39 -9.37
Diacylhydrazine # 28 0.74 -0.137 -8.61
Diacylhydrazine # 37 0.38 -0.42 -7.50
Diacylhydrazine # 18 3.69 0.57 -7.37
Diacylhydrazine # 38 0.99 -0.001 -7.27
Diacylhydrazine # 36 2.46 0.397 -6.59
doi:10.1371/journal.pntd.0004772.t001
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BmaEcR homology model. Thus, it was of interest to determine if these compounds could elicit
a similar response. As predicted, gravid adult female worms cultured in presence of 10 μM
muristerone A and ponasterone A exhibited a significant increase (p<0.001, t-test) in expul-
sion of aborted eggs, embryos and microfilariae as compared to the parasites cultured in the
presence of the 20E (Fig 8).
Discussion
Brugia malayi is an ecdysozoan that exhibits molting and developmental changes during the
lifecycle similar to those seen in arthropods. Studies have shown a high expression of the
BmaEcR transcripts in B.malayi in adult females, L3, eggs and embryos and mature microfilar-
iae [23]. In keeping with this expression pattern, recent studies have demonstrated that 20E
affected egg development and embryognesis in adult female B.malayi [45]. The data presented
above, though limited, suggests that 20E also interferes with the development of infective larvae
to adult parasites, a process involving two molts. In these studies, animals infected with L3,
when treated with 20E for 150 days (the time necessary for the parasites to develop from L3 to
fecund adult parasites) exhibited a dramatic decrease in the number of adult worms recovered
after treatment, along with a complete inhibition of microfilarial production. While the experi-
ment was designed to look for an effect at any point during this prolonged devellopmental
process, it is likely that 20E was actually interfering with some temporally limited critical devel-
opmental processes ocurring during this period, such as the L3-L4 molt or the molt from L4 to
immature adult parasites. Thus, treatment throughout the entire 150 day period may have not
been necessary. In support of this hypothesis, L3-stage larvae cultured in-vitro in the presence
of 20E molt earlier (on day 7–8) when compared with larvae cultured in the absence of 20E,
which between day 9–11 (S4 Table). It is therefore possible that administration of 20E results
in inappropriate activation of the BmaEcR, resulting in premature molting and death of the
developing parasites in vivo. This result, when combined with the effect of 20E on cultured
Fig 7. Structure and EC50 values of the compounds predicted to beBmaEcR ligands using the in-
silico virtual screeningmethod.
doi:10.1371/journal.pntd.0004772.g007
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adult females, suggests that 20E has effects on both embryogenesis and development of B.
malayi from the infective larvae stage to the adult stage. This finding would be similar to the
role that 20E plays in insects, where is serves as a master regulator of both vitellogenesis and
molting [46]. Further, these observations suggest that agonists of 20E may represent an impor-
tant potential chemotherapeutic space for the development of novel drugs against the human
filaria.
Previous studies demonstrated that mammalian cells transfected with plasmids encoding
three individual ORFs could be used to detect activation of the BmaEcR [13]. The initial assay
utilized NIH3T3 cells, which grow slowly and are therefore not optimal for use in a high
throughput assay format, where large quantities of cells are required. For this reason, we
decided to attempt to utilize HEK293 cells, which grow more quickly and therefore would be
more useful for high throughput assays. The assay, when optimized with HEK293 cells, dem-
onstrated an improved signal to noise ratio and Z’ value when compared to the transient
transfection assay utilizing NIH3T3 cells (S5 Table). However, because the assay relied on tran-
siently transfected cells, it was cumbersome and subject to day to day variations. For this rea-
son, we developed a cell line into which all three of the necessary cassettes were inserted into
the host cell’s genome. This assay exhibited performance characteristics that equaled or
exceeded those of the original assay, making it much more amenable to a high throughput
format.
Fig 8. In-vitro phenotypic study demonstrating effect of Ponasterone A, Muristerone A and 20E on adult female worms. The bars depict
counts of progeny expelled per ml of media. 1 and 2 represent two biological replicates of the treated and control for the expulsed progeny. The
error bars denote the standard deviation of the technical replicates. The colored bars represent each consecutive day of the experiment.
doi:10.1371/journal.pntd.0004772.g008
Therapeutic Potential of B.malayi Ecdysone Receptor
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004772 June 14, 2016 14 / 19
As a first test of the assay, a small library of compounds that have previously been shown to
act as ligands for EcRs of other species, as well as ligands for other members of the NHR family
were screened for activity aginst the BmaEcR. The results of this study suggested that members
of the diacylhydrazine (DAH) family were active ligands for the BmaEcR. This class of com-
pounds has been previously exploited by the agricultural industry to develop insecticides tar-
geting insect EcRs. The DAHs cause precocious molting, leading to the death of the the target
organism. These compounds also show high species specificity. Furthermore, there is no evi-
dence of detrimental effects of DAH on the vertebrates. Taken together, these data suggest that
members of the DAH family may have good potential as chemotherapeutic agents against the
filaria.
As described above, ecdysone analogs (both steroidal and non-steroidal) often demonstrate
species-specific activities. In the studies reported here, we see similar evidence of species-spe-
cific activities for compounds active against the BmaEcR. For example, muristerone A, a
known ecdysone analog, was one of the compounds in the library tested with the BmaEcR cell
based assay. Muristerone A has demonstrated activity in the insect system [47], but it did act as
an agonist when tested against the BmaEcR.
Apart from the DAH family, several other families of compounds, including the tetrahydro-
quinolones, butyl-benzamide and acylaminoketone, have been shown to act as ecdysone ago-
nists. Other potential sources of chemotherapeutic agents may include compounds showing
activity against other members of the NHR family; e.g., natural extracts from plants and fungi.
The development of the assay based upon the stable cell line described above should be useful
in implementing high-throughput screens to identify potential additional leads from these
sources.
To complement the high throughput assay, a homology model was also created to permit
in-silico screening of potential ligands against the BmaEcR. When using homology models to
predict ligand binding, it is important to verify whether the resulting models are: a) likely to be
found in nature, b) structurally relatable to other proteins in their family (i.e., have the same
overall fold), and c) are reproducible. Analysis presented via Ramachandaran plots and the
direct comparison to known protein relatives together suggests that the homology model
reported above meets these critera and that it closely represents the true structure of the
BmaEcR LBD. Furthermore, the model reflects the known mechanism of binding of the EcR to
its cognate ligand, in that upon binding of 20-hydroxyecdysone, a conformational change
allows H12 to interact with the ecdysone response elements present in the promoters of ecdy-
sone responsive genes, activating transcription. The fact that the model captures this mechanis-
tic feature provides added support for its potential utility in virtual screening studies.
In the analysis of predicted binding poses for each ligand, a pattern was observed: orienta-
tion of the potential steroidal ligands were optimized such that hydrophobic tails were buried
in a hydrophobic region, while the central steroid nucleus structure was surrounded by more
hydrogen bond donating/accepting side-chains. When the agonists identified in our prelimi-
nary screen were docked in the BmaEcR LDB, they interacted almost exclusively with the
hydrophobic region, resulting in very favorable hydrophobic enclosure and lipophilic terms (as
listed in XP energy decomposition analyses, Table 1). The DAH family occupied a very differ-
ent orientation in the active site when compared to the steroidal ligands, yet displayed compa-
rable activity to stimulate the receptor.
Ponasterone A and muristerone A displayed a higher fold change activity than 20E in the
stable cell line assay as well as being predicted to bind firmly in the active site of the BmaEcR
homology model. In confirmation of this, ponasterone A and muristerone A increased expul-
sion of microfilariae and aborted eggs and embryos from adult female parasites cultured in
their presence. This short-term culture assay can therefore be of use in providing a preliminary
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confirmation of the biological activity of potential leads identified in the high throughput and
in-silico screens prior to undertaking time consuming and expensive in-vivo studies in infected
animals.
In conclusion, the data presented here validate the filarial ecdysone receptor as a potential
chemotherapeutic target, and describe a series of assays that can be used to identify and validate
potential lead compounds against this target. Given the success of the agricultural industry in
targeting this receptor, these studies lay the groundwork for the exploitation of this receptor to
develop anti-filarial agents that could supplement those currently used in the elimination pro-
grams worldwide.
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